Synopsis
Introduction
Intra-operative cytology is an important predictor of peritoneal recurrence (Kitamura, Arai, Iwasaki et al., 1999) and is defined as a poor prognostic factor according to the general rules for the gastric cancer study in Japan (13th edition, Japanese Research Society for Gastric Cancer) because there is no effective chemotherapy for peritoneal dissemination (Arai, Iwasaki, Takahashi et al., 2001 ).
S-I is a novel oral anti-cancer drug and it was reported to be effective in 49% of the patients with gastric cancer (Sakata, Ohtsu, Horikoshi et al., 1998) . There are many reports about the efficacy of S-1 against liver metastases, lymph node metastases and peritoneal dissemination (Kawai, Ohtsu Boku et al., 2003; Osugi, Takada, Takemura et al., 2002) . Iizuka reported that the serum and intra-abdominal concentrations of 5-FU after the administration of S-1 were almost equal (Iizuka, Takahashi, Kakihara et al., 2002) . Moreover, the level of 5-FU in ascites after administration of S-1 was found to be higher than that after the administration of other 5-FU-containing anti-cancer drugs (Seki, Takahashi, Kimura 1987) . Thus, S-1 would be effective in patients with gastric cancer and positive cytology ascites. In this retrospective study we examined the clinical efficacy of S-1 in the patients with advanced gastric cancer and positive cytology. years (50 to 84). In the S-1 group there were none of differentiated adenocarcinoma and 12 of undifferentiated adenocarcinoma. In the 5-FU group there were 3 cases of differentiated adenocarcinoma and 11 of undifferentiated adenocarcinoma Table I . orally at a dose of 80-120 mg/day. One course consisted of S-1 for 28 consecutive days followed by rest for 14 days. Oral 5-FU was administered continuously at a dose of 150 mg/day without rest. Informed consent was obtained regarding the administration of S-1.
The mean survival time (MST) of each group was examined and compared. The survival rate was calculated by the Kaplan-Meier method and survival curve differences were measured with the log-rank tests. Statistical significance was assumed for P values of less than 0.05.
Results
The MST of the S-1 group was 579 days and that of the 5-FU group was 211 days. As for the 19 resected cases , the MST of the S-I group was 768 days, and that of the 5-FU group was 215 days . The survival rate of the S-1 group was significantly higher ascites of the administration of S-1 were found to be observed higher than other 5-FUcontaining anticancer drug (Seki, Takahashi, Kimura et al., 1987) . Thus, S-1 might be effective against peritponeal dissemination.
The survival rate of the S-1 group was significantly higher than that of the 5-FU group and the MST of the S-1 group was the same or longer than that found in other studies (Nomura, Niki, Fujii et al., 2001; Nor, Yoo, Chung et al., 2001; Yonemura, Fujimura, Fushida et al., 1999) . The same result was obtained in the resected cases, indicating that S-1 was useful drug not only as chemotherapy for peritoneal dissemination but also as post-operative adjuvant chemotherapy in patients with advanced gastric cancer and positive cytology.
Osugi et al. reported the efficiency of S-1 for gastric cancer patients with positive cytology (Osugi , Takada, Takemura 2002) . They did not refer to the difference of the two ANNALS OF Cancer Research and Therapy groups including the patients who did not undergo laparotomy in only S-1 group. In our report all patients underwent laparotomy and there was no significant difference between two groups. S-1 is an anti-cancer drug for oral use, thus it contributes to the patient's QOL.
This was a retrospective study and the cases were only 26, therefore it is important to conduct a randomized control trial involving a larger number of patients to evaluate the usefulness of S-1 as adjuvant chemotherapy for patients with advanced gastric cancer and positive cytology.
